{"id":5596,"date":"2012-02-06T09:00:00","date_gmt":"2012-02-06T09:00:00","guid":{"rendered":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/"},"modified":"2024-09-23T11:22:46","modified_gmt":"2024-09-23T11:22:46","slug":"klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief","status":"publish","type":"post","link":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/","title":{"rendered":"Klinische test met vaccinatie met GAD-alum nog niet erg positief"},"content":{"rendered":"Behanding van recent gediagnostiseerde T1D pati\u00ebnten met GAD-alum heeft nog geen overtuigend resultaat. Het lichaam produceert een eiwit genaamd GAD65, dat veel voorkomt in de pancreas. Bij T1D maakt het afweersysteem onder meer antilichamen aan tegen dit eiwit. In een fase 2 onderzoek was gebleken dat vaccinatie met GAD-alum deze afweerreactie vermindert en ook de afbraak van beta cellen tegen gaat. In een klinische fase 3 test probeerden onderzoekers 334 T1D pati\u00ebnten te vaccineren met behulp van GAD-alum. De resultaten zijn teleurstellend, in de zin dat het algehele resultaat negatief is. Wel zijn er kennelijk omgevingsfactoren in het spel, zoals seizoensinvloeden, leeftijd, geslacht en andere vaccinaties. Men zoekt verder in langduriger trials, wordt vervolgd.\n\n<a href=\"http:\/\/medicalxpress.com\/news\/2012-02-seasonal-efficacy-vaccination-diabetes.html\">Lees verder (Engelstalig)<\/a>","protected":false,"raw":""},"excerpt":{"rendered":"<p>Behanding van recent gediagnostiseerde T1D pati\u00ebnten met GAD-alum heeft nog geen overtuigend resultaat. Het lichaam produceert een eiwit genaamd GAD65, dat veel voorkomt in de pancreas. Bij T1D maakt het afweersysteem onder meer antilichamen aan tegen dit eiwit. In een fase 2 onderzoek was gebleken dat vaccinatie met GAD-alum deze afweerreactie vermindert en ook de [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[184],"tags":[],"class_list":["post-5596","post","type-post","status-publish","format-standard","hentry","category-archief"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Klinische test met vaccinatie met GAD-alum nog niet erg positief - Breakthrough T1D<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Klinische test met vaccinatie met GAD-alum nog niet erg positief - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Behanding van recent gediagnostiseerde T1D pati\u00ebnten met GAD-alum heeft nog geen overtuigend resultaat. Het lichaam produceert een eiwit genaamd GAD65, dat veel voorkomt in de pancreas. Bij T1D maakt het afweersysteem onder meer antilichamen aan tegen dit eiwit. In een fase 2 onderzoek was gebleken dat vaccinatie met GAD-alum deze afweerreactie vermindert en ook de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:published_time\" content=\"2012-02-06T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T11:22:46+00:00\" \/>\n<meta name=\"author\" content=\"ylt-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"ylt-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/\"},\"author\":{\"name\":\"ylt-admin\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\"},\"headline\":\"Klinische test met vaccinatie met GAD-alum nog niet erg positief\",\"datePublished\":\"2012-02-06T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/\"},\"wordCount\":129,\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"articleSection\":[\"Archief\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/\",\"name\":\"Klinische test met vaccinatie met GAD-alum nog niet erg positief - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\"},\"datePublished\":\"2012-02-06T09:00:00+00:00\",\"dateModified\":\"2024-09-23T11:22:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breakthrought1d.eu\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Klinische test met vaccinatie met GAD-alum nog niet erg positief\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#website\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Wij zetten ons in voor een toekomst zonder T1D\",\"publisher\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"contentUrl\":\"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png\",\"width\":330,\"height\":141,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6\",\"name\":\"ylt-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g\",\"caption\":\"ylt-admin\"},\"sameAs\":[\"https:\/\/87.250.144.92\"],\"url\":\"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Klinische test met vaccinatie met GAD-alum nog niet erg positief - Breakthrough T1D","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/","og_locale":"nl_NL","og_type":"article","og_title":"Klinische test met vaccinatie met GAD-alum nog niet erg positief - Breakthrough T1D","og_description":"Behanding van recent gediagnostiseerde T1D pati\u00ebnten met GAD-alum heeft nog geen overtuigend resultaat. Het lichaam produceert een eiwit genaamd GAD65, dat veel voorkomt in de pancreas. Bij T1D maakt het afweersysteem onder meer antilichamen aan tegen dit eiwit. In een fase 2 onderzoek was gebleken dat vaccinatie met GAD-alum deze afweerreactie vermindert en ook de [&hellip;]","og_url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/","og_site_name":"Breakthrough T1D","article_published_time":"2012-02-06T09:00:00+00:00","article_modified_time":"2024-09-23T11:22:46+00:00","author":"ylt-admin","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"ylt-admin","Geschatte leestijd":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/#article","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/"},"author":{"name":"ylt-admin","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6"},"headline":"Klinische test met vaccinatie met GAD-alum nog niet erg positief","datePublished":"2012-02-06T09:00:00+00:00","dateModified":"2024-09-23T11:22:46+00:00","mainEntityOfPage":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/"},"wordCount":129,"publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"articleSection":["Archief"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/","url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/","name":"Klinische test met vaccinatie met GAD-alum nog niet erg positief - Breakthrough T1D","isPartOf":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#website"},"datePublished":"2012-02-06T09:00:00+00:00","dateModified":"2024-09-23T11:22:46+00:00","breadcrumb":{"@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/klinische-test-met-vaccinatie-met-gad-alum-nog-niet-erg-positief\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breakthrought1d.eu\/nl\/"},{"@type":"ListItem","position":2,"name":"Klinische test met vaccinatie met GAD-alum nog niet erg positief"}]},{"@type":"WebSite","@id":"https:\/\/breakthrought1d.eu\/nl\/#website","url":"https:\/\/breakthrought1d.eu\/nl\/","name":"Breakthrough T1D","description":"Wij zetten ons in voor een toekomst zonder T1D","publisher":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breakthrought1d.eu\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/breakthrought1d.eu\/nl\/#organization","name":"Breakthrough T1D","url":"https:\/\/breakthrought1d.eu\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","contentUrl":"https:\/\/breakthrought1d.eu\/nl\/wp-content\/uploads\/2024\/11\/BTlogo.png","width":330,"height":141,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/c141fde9814deb17e9eb392bdb6619a6","name":"ylt-admin","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/breakthrought1d.eu\/nl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a3317a8082bc0f586c2e46f82a1617530cf674f2027a1a7d60fdff63a2c3e8?s=96&d=mm&r=g","caption":"ylt-admin"},"sameAs":["https:\/\/87.250.144.92"],"url":"https:\/\/breakthrought1d.eu\/nl\/nieuws\/author\/ylt-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/comments?post=5596"}],"version-history":[{"count":1,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5596\/revisions"}],"predecessor-version":[{"id":7334,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/posts\/5596\/revisions\/7334"}],"wp:attachment":[{"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/media?parent=5596"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/categories?post=5596"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breakthrought1d.eu\/nl\/wp-json\/wp\/v2\/tags?post=5596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}